AllDocs -> cancers

leukaemia Institute of Child Health & Great Ormond Street Hospital Molecular Basis of Childhood Leukaemia Thursday 23 – Friday 24 March 2006 Provisional Programme Thursday 23 rd March 2006 Introduction Hugh Brady, Institute of Child Health The MLL Gene and Leukaemia 10.00 MLL fusion genes: what do they tell us about acute leukaemia ? Eric So, Institute of Cancer Research, London MLL fusions in leukaemia : different proteins, one function? Robert Slany, University of Erlangen 11.20 T e a / c o f f e e 11.50 Pathological mechanisms in t(4;11) leukaemia : new insights and perspectives Rolf Marschalek, University of Frankfurt 12.30 MLL - Leukaemia and ...

Accreditation check list for centres offering specialist training in Paediatric Haematology and Oncology Prepared by the Education and Training Committee of SIOP Europe and ESPHI. February 10, 2003 10/05/04 1 Page 2 CONTENTS Page No. Title page 1 Index 2 Introduction 3 Statistics of Centre’s activity 4 Accreditation Check List: General requirements 5 Haematology 15 Neuro-oncology 17 Other solid tumours 20 Bone marrow/stem cell transplant 22 Adolescent oncology 25 Phase I/II trials 26 Late effects 27 10/05/04 2 Page 3 Introduction It is envisaged that this document will be used as a checklist at an accreditation visit to a centre/centres offering a training programme in paediatric haematology ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 4 January 2006 Doc.Ref.: EMEA/COMP/221755/2005 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF troxacitabine for the treatment acute myeloid leukaemia On 26 August 2005, orphan designation (EU/3/05/311) was granted by the European Commission to GMG BioBusiness United Kingdom, for troxacitabine for the treatment of acute myeloid leukaemia . What is acute myeloid leukaemia ? Acute myeloid leukaemia is a disease ...

1 Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulphate proteoglycan Nina Kureishy, Daisy Faruque and Colin D. Porter 1 The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK Running title: Primary attachment of MLV 1 Corresponding author: Dr. C. D. Porter, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK Telephone: +44 (0)207 153 5152 FAX: +44 (0)207 352 3299 e-mail: colin.porter@icr.ac.uk Biochemical Journal Immediate Publication. Published on 8 Aug 2006 as manuscript BJ20060825 Copyright 2006 Biochemical Society Page 2 2 SYNOPSIS Target cell entry of murine leukaemia virus vectors proceeds via primary attachment, independent of the viral envelope protein, and subsequent envelope/receptor ...

8. Hehlmann R, et al. Randomized comparision of Inter- feron-Alpha with Busulfan and Hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 382a 9. Fujita T, Kimura Y, Miyamoto M, et al. Induction of endogenous IFN-a and IFN-ß genes by a regulatory trans- cription factor, IRF-1. Nature 1989; 337: 270-272. 10. Fujita T, Reis LF, Watanabe N, et al. Induction of the transcription factor IRF-1 and interferon mRNAs by cyto- kines and activators of second-messenger pathways. Proc Natl Acad Sci USA 1989; 86: 729-739. 11. Carella AM, Podesta M, Frassoni F, et al. Collection of "normal" blood repopulating cells during early hema- topoietic recovery after intensive conventional chemo- therapy in chronic myelogenous leukemia. Bone Marrow Transplantation 1993; 12: 267-271. 12. McGlave PB, De Fabritis P, Deisseroth A, et al. Auto- logous transplants for chronic myelogenous leukaemia : results ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 29 November 2005 Doc.Ref.: EMEA/COMP/10370/2003 Rev.1 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF imatinib mesilate for treatment of chronic myeloid leukaemia On 14 February 2001, orphan designation (EU/3/01/021) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of chronic myeloid leukaemia . What is chronic myeloid leukaemia ? ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 29 November 2005 Doc.Ref.: EMEA/COMP/244140/2005 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF imatinib mesilate for the treatment of acute lymphoblastic leukaemia On 26 August 2005, orphan designation (EU/3/05/304) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of acute lymphoblastic leukaemia . What is acute lymphoblastic leukaemia ...

Flow Cytometry Immunophenotyping of Leukaemia and Lymphoma A one-day meeting organised by the RMS and the Institute of Cancer Research The Conference Centre, Royal Marsden Hospital, London Monday 26 April 2004 Organiser: Ricardo Morilla, Department of Haemato-Oncology, Royal Marsden Hospital This well established annual flow cytometry meeting on immunophenotyping is ideal for people in the field who like to remain updated on the recent advances in immunophenotyping and flow cytometry in general. The aim of the meeting is to discuss the main aspects of the use of flow cytometry in the diagnosis of leukaemia and lymphoma. The intention is to present a balanced program which will include both research developments in the field and routine problems encountered by those using flow cytometers on a daily basis. The meeting will be of interest to experienced individuals and to those ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 12 December 2005 EMEA/COMP/378/2004 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF aplidine for the treatment of acute lymphoblastic leukaemia On 9 July 2003, orphan designation (EU/3/03/151) was granted by the European Commission to Pharma Mar SA Sociedad Unipersonal, Spain, for aplidine for the treatment of acute lymphoblastic leukaemia . What is acute lymphoblastic leukaemia ? Acute lymphoblastic ...

Hans Karow Coalition to Reduce Electropollution (CORE) 1215 Poplar Grove Road PENTICTON, BC E-mail: hkarow@shaw.ca Mr. Robert J. Pellatt Commission Secretary British Columbia Utilities Commission Sixth Floor, 900 Howe Street, Box 250 Vancouver, BC, V6Z 2N3 Tel.: (604) 660 4700, Fax: (604) 660 1102 E-mail: Commission.Secretary@bcuc.com Via E-mail December 2, 2005 Dear Mr. Pellatt, Re: FortisBC Inc. Order No. G-114-05 / Project No. 3698407Certificate of Public Convenience and Necessity Application for Nk’Mip East Osoyoos Transmission and Substation http://www.bcuc.com/ApplicationView.aspx?ApplicationId=93 Please accept this submission into subject hearing as my Evidence # 7 which evidence I will refer to during the course of the subject hearing process. Yours truly, Hans Karow Source: http://www.i-sis.org.uk/NTEFE.php ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 29 November 2005 Doc.Ref.: EMEA/COMP/10370/2003 Rev.1 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF imatinib mesilate for treatment of chronic myeloid leukaemia On 14 February 2001, orphan designation (EU/3/01/021) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of chronic myeloid leukaemia . What is chronic myeloid leukaemia ? ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 29 November 2005 Doc.Ref.: EMEA/COMP/244140/2005 COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF imatinib mesilate for the treatment of acute lymphoblastic leukaemia On 26 August 2005, orphan designation (EU/3/05/304) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of acute lymphoblastic leukaemia . What is acute lymphoblastic leukaemia ...

To make a donation, or request more information about Cure Leukaemia and/or Support Groups, please fill in your details and send to the Fundraising Office. Title: Initial(s): . Surname: .. Address: .. .. Postcode: . Telephone: . Email: .. I enclose a donation of £ (please make cheques payable to Cure Leukaemia ) Or: Please send me further information about Cure Leukaemia and Support Groups Gift Aid Increase the value of your donation by 28% by ticking the Gift Aid declaration. I confirm that I am a UK tax payer. I pay an amount of income tax or capital gains tax at least equal to the tax that Cure Leukaemia will reclaim from the Inland Revenue on my donation...§ Under the terms of the Data Protection Act, Cure Leukaemia will retain and use the data you have provided for administrative purposes and to inform you of its fundraising and other activities. ...

Our Patrons • The development of three different experimental antibody-based drugs that selectively kill leukaemia cells. • The conduct of three separate early clinical trials with two of these drugs to evaluate their safety profiles and anti- leukaemia potencies in patients. • The first group in the UK to provide an antibody-based drug for use in a clinical trial for children with relapsed leukaemia . • Research results that reveal ways in which we can improve antibody type treatments for leukaemia that remain to be tested in clinical trials. • A strong ongoing commitment to research both nationally and internationally. • An ongoing research and discovery programme designed to maximise the effectiveness of antibody type therapies for the benefit of patients with leukaemia and other blood related disorders. Our Successes Fighting for ...

Leukaemia Busters Leukaemia Busters The Children’s Leukaemia Research Charity Telephone: 023 8063 6607 Fax: 023 8063 6609 Donations and correspondence should be sent to: Leukaemia Busters, Southampton General Hospital, Southampton SO16 6YD M M ARA ARA THON THON A A LIVE LIVE ! ! Forty three teams took part in the third 24 hour football marathon at Ashdown Leisure Centre in Poole organised once again by Gary and Jane Meech, aided by friends and relatives. Since the loss of their son Christopher to leukaemia five years ago, Gary and Jane have been committed fundraisers for Leukaemia Busters, raising a total of over £27,500 for the charity. This year’s event was no exception. Between them the teams scored over 327 goals and ...

1 A climax to the Leukaemia Busters’ Save Our Clinical Trials Campaign came on 2 nd February when a 21,000 signature petition was presented to the Prime Minister at 10 Downing Street. The campaign was launched as a response to a new European Clinical Trials Directive that will make it very difficult and prohibitively expensive for non- commercial organisations, including medical research charities, to conduct clinical trials. Leukaemia Busters have been campaigning hard since September 2003 to have the new regulations modified to take into account the special needs and unique contribution that The Children’s Leukaemia Research Charity Newsletter No.20, Spring/Summer 2004 www.leukaemiabusters.org.uk Phone: 023 8063 6607 Fax: 023 8063 6609 Email: info@leukaemiabusters.org.uk Donations and correspondence should be sent to: Leukaemia ...

RESEARCH ARTICLES CURRENT SCIENCE, VOL. 89, NO. 9, 10 NOVEMBER 2005 1571 *For correspondence. (e-mail: talwar37@rediffmail.com) Human acute lymphoblastic leukaemia cells make human pregnancy hormone hCG and expose it on the membrane: A case for using recombinant antibody against hCG for selective delivery of drugs and/or radiations Rafi Shiraz Kabeer 1 , Rahul Pal 2 and G. P. Talwar 1, * 1 Talwar Reasearch Foundation, E-8 Neb Valley, Neb Sarai, New Delhi 110 068, India 2 Immunoendocrinology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110 067, India The binding of a humanized chimeric (cPiPP) recombi- nant antibody (human IgG 1 , kappa linked to mouse variable regions) of high affinity (Ka 3 × 10 10 ...

IJI VOL. 2 NO. 3 Summer 2005 141 Glutathione S-transferases Null Genotype in Acute Myeloid Leukaemia Mohammad hasan Sheikhha 1* , Mehdi Kalantar 1 , Khalid Tobal 2 , John A. Liu Yin 3 1 Genetic Department, Clinical and Research Center for Infertility, Shahid Sadughi University of Medical Sciences, Yazd, Iran. 2 MRD Lab, King’s College, London, UK. 3 Department of Haematology, Manchester Royal Infirmary, Manchester, UK. ABSTRACT Background: The glutathione S-transferase (GST) family of metabolising enzymes plays an important role in the detoxification of mutagens and carcinogens. The expression of many of these cancer susceptibility enzymes is genetically polymorphic. An increased frequency of GST -null genotypes has been associated with several malignancies. Objective: ...

Glutathione S-transferases Null Genotype in Acute Myeloid Leukaemia Mohammad hasan Sheikhha 1* , Mehdi Kalantar 1 , Khalid Tobal 2 , John A. Liu Yin 3 1 Genetic Department, Clinical and Research Center for Infertility, Shahid Sadughi University of Medical Sciences, Yazd, Iran. 2 MRD Lab, King’s College, London, UK. 3 Department of Haematology, Manchester Royal Infirmary, Manchester, UK. ABSTRACT Background: The glutathione S-transferase (GST) family of metabolising enzymes plays an important role in the detoxification of mutagens and carcinogens. The expression of many of these cancer susceptibility enzymes is genetically polymorphic. An increased frequency of GST -null genotypes has been associated with several malignancies. Objective: To investigate the rate of GSTT1 and GSTM1 ...

Proceedings of the TTT2005 Academic Conference - 14 - The Effect of Arsenic Trioxide (ATO) on Human Leukaemia Cells Annie Hung-Hsin Liu Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan; Genomics Research Centre, School of Health Sciences and School of Biomolecular and Biomedical Sciences, Griffith Uiversity, Australia ABSTRACT Studies into the effects of toxins on cancer cells provide clues on how to induce apoptosis of malignant cells. Arsenic Trioxide (ATO) may be effective in inducing apoptosis in rapidly dividing cells. Arsenic compounds have been used in traditional Chinese medicine for thousands of years. Commonly known as a poison, it is also used to treat a variety of ailments from syphilis to cancer. The Food and Drug Administration (FDA) approved ATO for treatment against acute promyelocytic leukaemia (APL) in 2000 (Food and Drug Administration ...

Viruses, Koalas and Leukaemia Dr Jeff McKee – University of Queensland National Wildlife Rehabilitation Conference 2005 Page 1 of 7 VIRUSES, KOALAS AND LEUKAEMIA Dr Jeff McKee University of Queensland Are viruses alive? The jury is still out – however regardless of their taxonomic status no other entity has had more effect on the evolution and ecology of life on the planet. Every species - plant, animal or bacteria - examined so far has its own associated viruses which have diverse impacts both on individual hosts and host populations. The devastation of New World indigenous peoples by smallpox between 1600 and 1900 and the more recent emergence of HIV-AIDS are two graphic reminders of how viruses shape populations. Viruses were first discovered by two Danish investigators in 1908. Ellerman was a physician and Bang a veterinarian and together they were attempting to track ...

Acute leukaemia panel General Information Panel of markers used CD7,CD10 CD13,CD14 CD19 CD33 CD34, TdT • Specimen transport • Repeat frequency • Special conditions / precautions Laboratory Information Reporting Units Volume and Sample type Method Turnaround time (working days) . Percentage* 20mls EDTA blood or 5ml bone marrow in heparin with tissue culture medium Flow Cytometry Same day if sample received before noon Clinical Information • Indications for the test Suspected acute leukaemia • Factors affecting the test Clinical workstation reference: ACUTE Acute leukaemia panel 49 Page 2

Biochem. J. (1988) 250, 349-353 (Printed in Great Britain) Relationship between membrane sterol composition and responsiveness to 12-O-tetradecanoylphorbol 13-acetate in HL-60 human promyelocytic leukaemia cell lines Etienne MALVOISIN,*t Fabian WILDt and Georges ZWINGELSTEIN*t tUnite de Virologie fondamentale et appliquee, INSERM U.51, CNRS U.613, 1 Place Joseph Renaut, F-69371 Lyon Cedex, and *Laboratoire de Physiologie generale et comparee de L'Universite Claude Bernard Lyon 1, 43 Boulevard du 11 Novembre 1918, F-69622 Villeurbanne Cedex, France We have examined the sterol composition and metabolism of promyelocytic ...

Biochem. J. (1988) 254, 95-100 (Printed in Great Britain) Uptake and metabolism of myo-inositol by L1210 leukaemia cells James D. MOYER, Nancy MALINOWSKI, Elizabeth A. NAPIER and John STRONG Laboratory of Biological Chemistry, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Building 37, Room 5D02, Bethesda, MD 20892, U.S.A. The initial rate ofuptake of[3H]myo-inositol by L1210 murine leukaemia cells is directly proportional to the extracellular concentration and unaffected by several analogues of myo-inositol even at millimolar concentrations. Scyllitol, a geometric isomer of myo-inositol, partially inhibited the uptake of myo-inositol (40 % at 0.1 mM). A portion ofthe uptake ofmyo-inositol was not inhibited even at 5 mM-scyllitol. ...

Biochem. J. (1985) 232, 605-607 (Printed in Great Britain) Gene expression of ornithine decarboxylase in L1210 leukaemia cells exposed to DL-2-difluoromethylornithine in the presence of cadaverine Leena ALHONEN-HONGISTO, Riitta SINERVIRTA, Olli A. JANNE* and Juhani JANNE Department of Biochemistry, University of Helsinki, SF-00170 Helsinki, Finland Cultured mouse L1210 leukaemia cells treated with DL-2-difluoromethylornithine, an irreversible inhibitor ofornithine decarboxylase (EC 4.1.1.17), in the presence ofmicromolar concentrations of cadaverine, started to overproduce ornithine decarboxylase after an exposure of ...

Biochem. J. (1995) 308,131-137 (Printed in Great Britain) Modulation of poly(ADP-ribose) polymerase during neutrophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells Mickie BHATIA, James B. KIRKLAND and Kelly A. MECKLING-GILL* Department of Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada Ni G 2W1 Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme which has been shown to play a role in the differentiation of haemato- poietic cells. We report here that neutrophils are the first nucleated mammalian cell type demonstrated to be devoid of immunoreactive PARP. Both NB4 ...

Biochem. J. (1994) 298, 149-156 (Printed in Great Britain) Analysis of protein kinase C requirement for exocytosis in permeabilized rat basophilic leukaemia RBL-2H3 cells: a GTP-binding protein(s) as a potential target for protein kinase C Roberto BUCCIONE,*tt Giuseppe DI TULLIO,* Massimiliano CARETTA,* Maria Rita MARINETTI,*II Cinzia BIZZARRI,tT Sandro FRANCAVILLA,t Alberto LUINI* and Maria Antonietta DE MATTEIS§ *Laboratory of Molecular Neurobiology, tLaboratory of Cellular and Molecular Endocrinology and §Pathophysiology of Secretion Unit, Istituto di Ricerche Farmacologiche 'Mario Negri', Consorzio Mario Negri Sud, 66030 S. Maria Imbaro (Chieti), and tLaboratory of Andrology, Dipartimento di Medicina Interna, ...

Biochem. J. (1989) 258, 903-906 (Printed in Great Britain) Abnormalities in the erythrocyte membrane in acute lymphoid leukaemia Manikuntala KUNDU,* Joyoti BASU,* Parul CHAKRABARTI*t and Madan Mohan RAKSHIT$ *Department of Chemistry, Bose Institute, 93/1 A.P.C. Road, Calcutta - 700 009, India, and tHaematology Unit, N.R.S. Medical College and Hospital, 138 A.J.C. Bose Road, Calcutta - 700 014, India Erythrocytes from patients suffering from acute lymphoid leukaemia (ALL) show decreased proportions of spectrin tetrameters and altered spatial distribution of band 4.1 and ankyrins. These abnormalities of the cytoskeleton are probably responsible for altered membrane fluidity and ...

Biochem. J. (1985) 227, 971-979 971 Printed in Great Britain Breakdown of phosphatidylinositol 4,5-bisphosphate in a T-celi leukaemia line stimulated by phytohaemagglutinin is not dependent on Ca2- mobilization Terukatsu SASAKI and Hiroko HASEGAWA-SASAKI Department of Biochemistry, Sapporo Medical College, Sapporo 060, Japan (Received 31 December 1984; accepted 10 January 1985) Addition of phytohaemagglutinin (PHA) to the [32P]Pi-prelabelled JURKAT cells, a human T-cell leukaemia line, resulted in a decrease of [32P]phosphatidylinositol 4,5- bisphosphate [PtdIns(4,5)P2] to about 35% ...